MAP2K7 and ovarian serous adenocarcinoma: Although VS-6766 (a RAF/MEK inhibitor) exhibited antitumor activity in platinum-resistant low-grade serous ovarian cancer and endometrial adenocarcinoma with RAF–RAS–MEK pathway mutations, patients later experienced progression.